Cancer diagnostic giant Telix Pharmaceuticals says the US Securities and Exchange Commission had issued it with a subpoena seeking information about disclosure related to the development of the company’s prostate cancer therapies.
Melbourne-based Telix said on Tuesday it had notified the Australian Securities and Investments Commission about the subpoena, which it called a “fact-finding request”.
Loading...
Michael Smith is the health editor for The Australian Financial Review. He is based in Sydney. Connect with Michael on Twitter. Email Michael at michael.smith@afr.com
